DoctorLaura Laslett

Senior Research Fellow - Epidemiology

Menzies Institute for Medical Research

  • Senior Research Fellow - Epidemiology
    Menzies Institute for Medical Research
  • +61 3 6226 7704 (Fax)
  • +61 3 6226 7736 (Work)
  • Menzies Institute for Medical Research, Menzies Institute for Medical Research, 356-02 Medical Science 2, Hobart CBD Campuses, TAS

RESEARCH SUMMARy

Dr Laslett is interested in sleep in people with multiple sclerosis, and how symptoms of MS explain the symptom experience in people living with MS.
She is also interested in education for people living with MS, to help them live better lives as they age.

FUNDED PROJECTS

  • CONSULTANCY/CONTRACT RESEARCH
    FEATURED
    Featured
    Australian MS Longitudinal study
    1 Jan 2014 - 30 Jun 2029
    People funded by this grant:
    • van der Mei I,
    • Taylor B,
    • Palmer A,
    • Laslett L,
    • Campbell J
    Project Total: $2,373,061; The main objectives of this project are: a) to continue the established multi-disciplinary research database for Australia with MS that will provide answers to important questions about the disease that are not able to be addressed by projects funded in the normal, relatively short cycle of research grants; b) to encourage nationwide (and international) multi-disciplinary collaboration on MS research projects, utilising valid and reliable measures that are internationally accepted and compatible wherever possible, and to lead by example in the unification of Australia's efforts to solve the various problems associated with MS; c) to reduce the cost of multi-disciplinary research on MS by provision of a large, well-characterised cohort of volunteer subjects for future studies. Funded by: Multiple Sclerosis Australia ($2,354,730); University of Tasmania.
  • GRANT
    Feasibility and acceptability of activity monitors and symptom tracker apps
    1 Aug 2025 - 31 Jul 2027
    People funded by this grant:
    • Laslett L,
    • van der Mei I,
    • Taylor B,
    • Honan C,
    • Bramich S
    Project Total: $24,999; Poor sleep is common in the community, but even more common in people living with MS. Poor sleep has serious impacts on health, including clinically important reductions in quality of life. Treatments to improve symptoms and sleep are urgently needed in people living with MS. To do that, we need to assess sleep in a better way than we do now. This research program will use activity monitors to investigate whether using activity monitors 24/7 for up to 21 days and daily assessment of MS symptoms using the My Symptoms app for up to 21 days is feasible and acceptable, what the shortest duration of assessment is that will still give good quality data, and whether we can predict who will not want to use actigraphs and symptom trackers, and, when used, whether they provide better data on sleep, over and above that captured by standard questionnaires. We will use learnings to plan and appropriately power future clinical trials for sleep in people living with MS. Funded by: Multiple Sclerosis Australia - Grant-Incubator ($24,335); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    MS Trial Screen
    1 Jul 2024 - 30 Jun 2027
    People funded by this grant:
    • van der Mei I,
    • Laslett L
    Project Total: $160,615; MS Trial Screen is a platform that will act as a one-stop-shop for Australians living with MS who want to register and access cutting edge clinical trials. Using a secure internet-based portal accessible from any internet-enabled device, consumers will be able to register and determine if they meet criteria for clinical trials currently recruiting in Australia. Funded by: Multiple Sclerosis Australia ($160,615); University of Tasmania.
  • GRANT
    Pathways to treatments for better sleep in people with MS
    1 Jan 2024 - 31 Dec 2026
    People funded by this grant:
    • Laslett L
    Project Total: $225,000; Funded by: Multiple Sclerosis Australia - Fellowship-Postdoctoral ($225,000); University of Tasmania.
  • UTAS INTERNAL FUNDING
    The feasibility of using wearable devices to assessing sleep and a symptom tracker app to assess MS symptoms in Tasmanians living with multiple sclerosis
    2 May 2023 - 31 Oct 2023
    People funded by this grant:
    • Laslett L,
    • van der Mei I,
    • Taylor B,
    • Honan C,
    • Bramich S
    Project Total: $16,000; Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system. While MS remains rare, MS is more common in Tasmania (per capita) than elsewhere in Australia(1). Poor sleep is common in the community and even more common in people with MS (pwMS) (2) and include insomnia, sleep apnoea, and restless leg syndrome(3-8). A recent paper from CIs Laslett, van der Mei, Taylor and Honan demonstrates that two thirds of Australians with MS have sleep quality in the clinically poor range(2). We showed poor sleep is strongly associated with worse health related quality of life independent of MS symptoms and obesity(2). Deficits in quality of life due to poor sleep are in the clinically relevant range. By attempting to understand dysfunctional sleep in MS we have an opportunity to improve quality of life and make a difference in the lives of people with MS. To demonstrate we can use activity monitors to collect sleep data (24/7, 7-14 days). Demonstrate that using the My SymptoMS app daily is acceptable to pwMS. Evaluate the optimal duration by which activity monitors should be used to reliably measure sleep in pwMS without overburdening participants (7 vs 14 days). Validate sleep data from My SymptoMS compared to data from activity monitors and questionnaires. Investigate associations between activity-monitor assessed outcomes and quality of life, and symptoms using the My SymptoMS app. Funded by: Menzies Institute for Medical Research; University of Tasmania ($16,000).
  • GRANT
    Providing high-value care for osteoarthritis patients at the Royal Hobart Hospital (RHH)
    1 Jan 2020 - 30 Jun 2023
    People funded by this grant:
    • Aitken D,
    • Laslett L,
    • Harvie P,
    • Haward C
    Project Total: $12,940; This prospective, observational study will recruit patients undergoing primary elective hip or knee joint replacement at study sites in Tasmania. Participants will complete patient reported outcome measure (PROMs) surveys and have accelerometry data collected preoperatively and at 6 weeks, 12 weeks, 6 months and 12 months post-operatively. The trajectory of their recovery is measured both by their subjective PROMs responses and objective movement data captured by accelerometry to provide insights into expected performance changes and evaluate PROMs characteristics. The project aims to quantify physical performance changes that occur in patients following hip or knee arthroplasty and compare the relationship between this objective data and subjective PROMs. Funded by: The MPST Foundation Ltd - Grant ($12,940); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    A randomised trial of krill oil for osteoarthritis of the knee
    1 Jan 2019 - 31 Dec 2019
    People funded by this grant:
    • Jones G,
    • Wluka A,
    • Hill C,
    • March L,
    • Keen H
    Project Total: $100,000; This project is additional funding to NHMRC Grant J23281 Knee osteoarthritis (OA) is a significant and increasing cause of pain and disability in the aging Australian population, but interventions aimed at structural modification have been disappointing. Pilot data shows that krill oil reduces knee pain and systemic inflammation after 30 days, suggesting that an approach targeted at specific mechanisms of disease is effective in reducing painful OA. However, this pilot study was short, did not collect any data on structural factors, and included patients with a variety of disorders. We aim to compare, using a randomised, placebo-controlled double-blind design over six months, the efficacy of krill oil vs placebo in the treatment of osteoarthritis (OA) of the knee in 260 patients with clinical knee OA, significant knee pain and effusions, both with regard to control of symptoms and localised inflammation. Key hypothesis: Krill oil decreases pain (assessed by 100mm VAS) by 10mm more than identical placebo over 24 weeks in patients with clinical knee OA, significant knee pain and effusions. Secondary hypotheses: Krill oil improves knee pain over 4, 8, 12, 16, and 20 weeks in patients with clinical knee OA. Krill oil decreases effusion size by 20% over 24 weeks in patients with symptomatic osteoarthritis of the knee and knee effusion. If krill oil can both improve symptoms and decrease effusion in OA it has the potential to slow progression to joint replacement. The proposed study represents an innovative approach to this and lends itself to easy implementation as krill oil is already available over-the-counter in Australian pharmacies. Funded by: Aker BioMarine ($100,000); University of Tasmania.
  • GRANT
    Assessing the Australian osteoarthritis landscape - GPs' surgeons' and patients attitudes towards and understandings of osteoarthritis
    1 Jan 2018 - 31 Dec 2018
    People funded by this grant:
    • Balogun S,
    • Aitken D,
    • Winzenberg T,
    • Hansen E,
    • Newsham-West H
    Project Total: $24,824; Osteoarthritis is a leading cause of pain and disability among older people and there is currently no cure. In recent years, there has been increasing concern about the discrepancies between care provided by health professionals and recommendations in osteoarthritis clinical practice guideline. For instance, in Australia, referral to a surgeon is five times more common than referral to allied health professionals that could help with conservative management. Furthermore, patients are ambivalent towards conservative management such as exercise, thinking it will be ineffective and may even cause harm to their already worn joints. The disconnect between practice guideline and care for patients with osteoarthritis limits optimal care. Therefore, this study aims to explore the attitudes towards and understanding of osteoarthritis held by Australian GPs, surgeons and patients with knee osteoarthritis. The overarching goal is to gather information needed to develop Australian-specific education and behaviour change programs for GPs, surgeons and osteoarthritis patients Funded by: University of Tasmania - Grant- Research Enhancement Program; University of Tasmania ($24,824).
  • GRANT
    The effect of krill oil on cartilage composition
    1 Apr 2016 - 31 Dec 2016
    People funded by this grant:
    • Laslett L,
    • Eathakkattu Antony B,
    • Aitken D
    Project Total: $30,000; Aims: to compare efficacy of krill oil vs identical placebo on cartilage composition (T2 mapping values) in 260 patients with clinical knee OA, significant knee pain and effusion on imaging, using a randomised, placebo- controlled double-blind design over six months in an NHMRC-funded clinical trial. Funded by: Menzies Institute for Medical Research - Grant - Development Grant; University of Tasmania ($30,000).
  • GRANT
    A randomised trial of krill oil for osteoarthritis of the knee
    1 Jan 2016 - 31 Dec 2019
    People funded by this grant:
    • Jones G,
    • Wluka A,
    • Hill C,
    • March L,
    • Keen H
    Project Total: $751,491; Knee osteoarthritis (OA) is a significant and increasing cause of pain and disability in the aging Australian population, but interventions aimed at structural modification have been disappointing. Pilot data shows that krill oil reduces knee pain and systemic inflammation after 30 days, suggesting that an approach targeted at specific mechanisms of disease is effective in reducing painful OA. However, this pilot study was short, did not collect any data on structural factors, and included patients with a variety of disorders. We aim to compare, using a randomised, placebo-controlled double-blind design over six months, the efficacy of krill oil vs placebo in the treatment of osteoarthritis (OA) of the knee in 260 patients with clinical knee OA, significant knee pain and effusions, both with regard to control of symptoms and localised inflammation. Key hypothesis: Krill oil decreases pain (assessed by 100mm VAS) by 10mm more than identical placebo over 24 weeks in patients with clinical knee OA, significant knee pain and effusions. Secondary hypotheses: Krill oil improves knee pain over 4, 8, 12, 16, and 20 weeks in patients with clinical knee OA. Krill oil decreases effusion size by 20% over 24 weeks in patients with symptomatic osteoarthritis of the knee and knee effusion. If krill oil can both improve symptoms and decrease effusion in OA it has the potential to slow progression to joint replacement. The proposed study represents an innovative approach to this and lends itself to easy implementation as krill oil is already available over-the-counter in Australian pharmacies. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Project ($1,502,982); University of Tasmania.
  • GRANT
    Is the use of thermocyclopad effective for knee pain?
    1 Jan 2016 - 30 Dec 2017
    People funded by this grant:
    • Jones G,
    • Laslett L
    Project Total: $50,336; Clinical trial to assess the efficacy daily use of the Niagara Thermo Cyclo Pad unit on the heat and vibrate settings, or the heat and vibrate settings plus use of the hand held unit will reduce knee pain, stiffness and symptoms over four weeks compared to the sham pad, for knee OA pain, function and stiffness. Funded by: CT Healthcare Pty Ltd - Clinical Trial ($50,336); University of Tasmania.
  • GRANT
    Clinical trials in osteoarthritis
    1 Jan 2014 - 11 Sep 2020
    People funded by this grant:
    • Laslett L
    Project Total: $304,596; Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Fellowship-Early Career ($609,192); University of Tasmania.
  • GRANT
    Does either zoledronic acid or denosumab change back pain and morphology of Modic changes: a randomised open label pilot study
    1 Jan 2014 - 30 Sep 2017
    People funded by this grant:
    • Laslett L,
    • Jones G
    Project Total: $30,000; This research aims to determine whether two different bone active medications (zoledronic acid 5mg; denosumab 60mg) will modify back pain and structural abnormalities over six months in people with severe back pain and certain changes on magnetic resonance imaging (MRI). This will allow us to decide whether these medications have a large enough effect to warrant further clinical study. Funded by: Arthritis Australia - Grant-Project ($30,000); University of Tasmania.
  • GRANT
    Testing new treatments for back pain: a randomised open label pilot study
    1 Jan 2014 - 31 May 2017
    People funded by this grant:
    • Laslett L,
    • Aitken D,
    • Jones G
    Project Total: $88,721; This project will conduct a randomised open label pilot study on two potential treatments for back pain targeting Modic changes (zoledronic acid or denosumab). Funded by: Tasmanian Community Fund - Grant ($88,721); University of Tasmania.
  • GRANT
    Humira for treatment of erosive hand osteoarthritis
    1 Jan 2013 - 31 Dec 2013
    People funded by this grant:
    • Laslett L
    Project Total: $50,000; Funded by: Arthritis Australia - Fellowship-Research ($50,000); University of Tasmania.
  • GRANT
    2012 OARSI Young Investigator Scholarship
    1 May 2012 - 30 Jun 2012
    People funded by this grant:
    • Laslett L
    Project Total: $6,242; Funded by: Osteoarthritis Research Society International - Scholarship-Exchange ($6,242); University of Tasmania.